Gelteq to Participate in the Benchmark Company 13th Annual Discovery Investor Conference

Rhea-AI Summary

Gelteq (NASDAQ: GELS), a company specializing in gel-based delivery solutions for various products including prescription drugs and pet care, has announced its participation in the Benchmark Company 13th Annual Discovery Investor Conference. The event will take place on December 11, 2024, at the New York Athletic Club in New York City.

Co-Founders Nathan Givoni (CEO) and Simon Szewach (Executive Chairman) will be available for one-on-one meetings with analysts and investors throughout the conference day. Interested attendees can arrange meetings through their Benchmark Company representative.

NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products, announces that its Co-Founders, CEO Mr. Nathan Givoni and Executive Chairman Mr. Simon Szewach, will be participating in the Benchmark Company 13^th Annual Discovery Investor Conference being held on Wednesday, December 11, 2024, at the New York Athletic Club in New York City.

Mr. Givoni and Mr. Szewach will be hosting one-on-one meetings with analysts and investors throughout the day. To schedule a one-on-one meeting with them, attendees should contact their Benchmark Company representative. Investors can attend the conference by registering here.

About Gelteq Inc.
Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. Gelteq is focused on advancing and commercializing its delivery solutions within five core verticals: pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications, and sports nutrition. Gelteq’s unique formulation directly addresses the issues associated with traditional drug delivery methods such as difficulty swallowing, taste of unpalatable ingredients, and dosage control. For more information, visit www.gelteq.com.

Contact:

CORE IR
516-222-2560
PR@gelteq.com

FAQ

When is Gelteq (GELS) participating in the Benchmark Company Conference?

Gelteq (GELS) is participating in the Benchmark Company 13th Annual Discovery Investor Conference on December 11, 2024, at the New York Athletic Club in New York City.

Who will represent Gelteq (GELS) at the 2024 Benchmark Conference?

Gelteq's Co-Founders Nathan Givoni (CEO) and Simon Szewach (Executive Chairman) will represent the company at the conference.

What type of meetings will Gelteq (GELS) conduct at the Benchmark Conference 2024?

Gelteq's executives will be hosting one-on-one meetings with analysts and investors throughout the conference day.

How can investors meet with Gelteq (GELS) representatives at the Benchmark Conference?

Investors can schedule one-on-one meetings through their Benchmark Company representative and can register for the conference through the provided registration link.